Screener
Avalo Therapeutics AVTX Total Cost of Revenue
Discontinued — last reported Q2 '25
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Avalo Therapeutics’s 10-Q, filed August 7, 2025.
- Filed
- Aug 7, 2025
- Fiscal quarter
- Q2 FY2025
- Calendar quarter
- Q2 2025
- Accession
- 0001628280-25-038575
| Line item | Three Months Ended / June 30, 2025 | Three Months Ended / June 30, 2024 | Six Months Ended / June 30, 2025 | Six Months Ended / June 30, 2024 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Cost of product sales | — | $343 | — | $263 |
| Research and development | 14,074 | 4,601 | 23,195 | 6,716 |
| General and administrative | 5,242 | 4,528 | 10,789 | 7,721 |
| Acquired in-process research and development | — | 103 | — | 27,641 |
| Total operating expenses | 19,316 | 9,575 | 33,984 | 42,341 |
| Loss from operations | (19,316) | (9,575) | (33,984) | (42,341) |
| Other (expense) income: |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's total cost of revenue?
- Avalo Therapeutics (AVTX) reported total cost of revenue of $0 in Q2 2025.
- How has Avalo Therapeutics's total cost of revenue changed year-over-year?
- Avalo Therapeutics's total cost of revenue decreased by 100.0% year-over-year, from $343K to $0.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Avalo Therapeutics's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude